| Cat.No. | Name | Information |
|---|---|---|
| M7527 | Gilteritinib | Gilteritinib is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. |
| M1641 | Quizartinib (AC220) | Quizartinib (AC220) is a uniquely potent and selective FLT3 inhibitor. |
| M43510 | Wu-5 | Wu-5 is a USP10 inhibitor that can inhibit FLT3 and AMPK pathways, induce FLT3-ITD degradation and induce apoptosis. |
| M20343 | WAY-299359 | WAY-299359 is a FLT3 inhibitor |
| M14901 | Tandutinib hydrochloride | Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. |
| M14899 | Gilteritinib hemifumarate | Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. |
| M14898 | Dovitinib lactate | Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. |
| M14897 | AMG 925 HCl | AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively. |
| M10850 | Luxeptinib | Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent, potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle blocking, apoptosis, or autophagy in acute myeloid leukemia. |
| M10334 | FF-10101 | FF-10101 is a novel irreversible FLT3 inhibitor. |
| M10328 | MRX-2843 | MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3 with IC50 values of 1.3 nM and 0.64 nM, respectively. |
| M10181 | STK321130 | STK321130, also known as FLT3-IN-2, is potent FLT3 inhibitor with IC50 of <1 μM. |
| M5311 | AMG 925 | AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively. |
| M5142 | G-749 | G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y), and Mer, respectively, showing lower potency against other tyrosine kinases. |
| M5026 | UNC-2025 | UNC2025 is a potent, ATP-competitive and highly orally active Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC50= 122 nM; Ki = 13.3 nM). UNC2025 exhibits an excellent PK properties. |
| M4646 | Crotonoside | Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML. |
| M3800 | CGP52421 | CGP52421 is a FLT3 inhibitor, which is also an metabolite of midostaurin (PKC412). |
| M3053 | TCS 359 | TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM. |
| M1828 | Tandutinib | Tandutinib (MLN518, CT53518) is an orally active multitargeted tyrosine kinase inhibitor of FLT3 (IC50 = 0.22 μM), and it also inhibits c-Kit and PDGFR with IC50 values of 0.17 μM and 0.20 μM, respectively. Tandutinib has the ability to cross the blood-brain barrier. |
| M1815 | KW-2449 | KW-2449 is a novel multitargeted kinase inhibitor of FLT3, ABL and Aurora kinase with IC50 values of 6.6 nM, 14 nM and 48 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
